NeoVolta, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting financial results for the first quarter of its fiscal year 2027.
CV Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting third-quarter net product sales of $3,028 thousand and a net loss of $93 thousand.
Smartbird, Inc. filed a Form 8-K on November 13, 2026, reporting a shareholder letter from CEO Nadia Carlsten and a press release announcing secured data center capacity to accelerate AI infrastructure deployment.
York Space Systems Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 13, 2026, covering the fiscal quarter ended September 30, 2026.
LaFayette Acquisition Corp. filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 13, 2026, reporting net income of $935,375 for the three-month period and marketable securities held in Trust of $118,913,115.
Nektar Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026.
OneIM Acquisition Corp. filed its Form 10-Q for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, covering results for both the three and nine months ended on that date.
Bolt Biotherapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a net loss of $4.422 million for the third quarter and an accumulated deficit of $480.328 million.
Nektar Therapeutics filed a Form 8-K on November 13, 2026, disclosing via Regulation FD that the company held $952.9 million in cash and investments in marketable securities as of September 30, 2026, and expects that balance to extend its cash runway into the third …
Silence Therapeutics plc filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter ended September 30, 2026, and disclosing a significant increase in cash and cash equivalents alongside a pending acquisition by Merck KGaA, Darmstadt, Germany.